Advertisement Mylan introduces Amlodipine and Valsartan tablets in US to treat hypertension - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Mylan introduces Amlodipine and Valsartan tablets in US to treat hypertension

Mylan has introduced Amlodipine and Valsartan Tablets, 5mg/160mg, 5mg/320mg, 10mg/160mg, 10 mg/320mg in the US market.

Amlodipine and Valsartan Tablets are the generic version of Swiss pharmaceutical firm Novartis’ Exforge Tablets.

The US Food and Drug Administration (FDA) has also granted approval for the company’s abbreviated new drug application (ANDA) for this product to treat hypertension.

The product is indicated to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Around 269 of Mylan ANDAs that represent $104.1bn in annual sales are still awaiting clearance from the FDA, with 44 of them being potential first-to-file opportunities, signifying $27.3bn in annual brand sales, for the year ending 30 June 2014.

The company offers a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications.

Additionally, the company provides a wide range of antiretroviral therapies, upon which about 40% of HIV/AIDS patients in developing countries depend.

Mylan also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 140 countries and territories.